Giridhar Mohan1, Sajal K Chattopadhyay2, Donatus U Ekwueme3, Susan A Sabatino3, Devon L Okasako-Schmucker1, Yinan Peng1, Shawna L Mercer1, Anilkrishna B Thota1. 1. Community Guide Branch, Division of Public Health Information Dissemination, Center for Surveillance, Epidemiology, and Laboratory Services, Centers for Disease Control and Prevention, Atlanta, Georgia. 2. Community Guide Branch, Division of Public Health Information Dissemination, Center for Surveillance, Epidemiology, and Laboratory Services, Centers for Disease Control and Prevention, Atlanta, Georgia. Electronic address: skc9@cdc.gov. 3. Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia.
Abstract
CONTEXT: The Community Preventive Services Task Force recently recommended multicomponent interventions to increase breast, cervical, and colorectal cancer screening based on strong evidence of effectiveness. This systematic review examines the economic evidence to guide decisions on the implementation of these interventions. EVIDENCE ACQUISITION: A systematic literature search for economic evidence was performed from January 2004 to January 2018. All monetary values were reported in 2016 US dollars, and the analysis was completed in 2018. EVIDENCE SYNTHESIS: Fifty-three studies were included in the body of evidence from a literature search yield of 8,568 total articles. For multicomponent interventions to increase breast cancer screening, the median intervention cost per participant was $26.69 (interquartile interval [IQI]=$3.25, $113.72), and the median incremental cost per additional woman screened was $147.64 (IQI=$32.92, $924.98). For cervical cancer screening, the median costs per participant and per additional woman screened were $159.80 (IQI=$117.62, $214.73) and $159.49 (IQI=$64.74, $331.46), respectively. Two studies reported incremental cost per quality-adjusted life year gained of $748 and $33,433. For colorectal cancer screening, the median costs per participant and per additional person screened were $36.63 (IQI=$7.70, $139.23) and $582.44 (IQI=$91.10, $1,452.12), respectively. Two studies indicated a decline in incremental cost per quality-adjusted life year gained of $1,651 and $3,817. CONCLUSIONS: Multicomponent interventions to increase cervical and colorectal cancer screening were cost effective based on a very conservative threshold. Additionally, multicomponent interventions for colorectal cancer screening demonstrated net cost savings. Cost effectiveness for multicomponent interventions to increase breast cancer screening could not be determined owing to the lack of studies reporting incremental cost per quality-adjusted life year gained. Future studies estimating this outcome could assist implementers with decision making. Published by Elsevier Inc.
CONTEXT: The Community Preventive Services Task Force recently recommended multicomponent interventions to increase breast, cervical, and colorectal cancer screening based on strong evidence of effectiveness. This systematic review examines the economic evidence to guide decisions on the implementation of these interventions. EVIDENCE ACQUISITION: A systematic literature search for economic evidence was performed from January 2004 to January 2018. All monetary values were reported in 2016 US dollars, and the analysis was completed in 2018. EVIDENCE SYNTHESIS: Fifty-three studies were included in the body of evidence from a literature search yield of 8,568 total articles. For multicomponent interventions to increase breast cancer screening, the median intervention cost per participant was $26.69 (interquartile interval [IQI]=$3.25, $113.72), and the median incremental cost per additional woman screened was $147.64 (IQI=$32.92, $924.98). For cervical cancer screening, the median costs per participant and per additional woman screened were $159.80 (IQI=$117.62, $214.73) and $159.49 (IQI=$64.74, $331.46), respectively. Two studies reported incremental cost per quality-adjusted life year gained of $748 and $33,433. For colorectal cancer screening, the median costs per participant and per additional person screened were $36.63 (IQI=$7.70, $139.23) and $582.44 (IQI=$91.10, $1,452.12), respectively. Two studies indicated a decline in incremental cost per quality-adjusted life year gained of $1,651 and $3,817. CONCLUSIONS: Multicomponent interventions to increase cervical and colorectal cancer screening were cost effective based on a very conservative threshold. Additionally, multicomponent interventions for colorectal cancer screening demonstrated net cost savings. Cost effectiveness for multicomponent interventions to increase breast cancer screening could not be determined owing to the lack of studies reporting incremental cost per quality-adjusted life year gained. Future studies estimating this outcome could assist implementers with decision making. Published by Elsevier Inc.
Authors: Terry C Davis; Connie L Arnold; Charles L Bennett; Michael S Wolf; Cristalyn Reynolds; Dachao Liu; Alfred Rademaker Journal: Cancer Epidemiol Biomarkers Prev Date: 2013-11-05 Impact factor: 4.254
Authors: David R Lairson; Melissa DiCarlo; Ronald E Myers; Thomas Wolf; James Cocroft; Randa Sifri; Michael Rosenthal; Sally W Vernon; Richard Wender Journal: Cancer Date: 2008-02-15 Impact factor: 6.860
Authors: Roy C Baron; Barbara K Rimer; Ralph J Coates; Jon Kerner; Geetika P Kalra; Stephanie Melillo; Nancy Habarta; Katherine M Wilson; Sajal Chattopadhyay; Kimberly Leeks Journal: Am J Prev Med Date: 2008-07 Impact factor: 5.043
Authors: Electra D Paskett; Mark Dignan; Aaron J Kruse-Diehr; Jill M Oliveri; Robin C Vanderpool; Mira L Katz; Paul L Reiter; Darrell M Gray; Michael L Pennell; Gregory S Young; Bin Huang; Darla Fickle; Mark Cromo; Melinda Rogers; David Gross; Ashley Gibson; Jeanne Jellison; Michael D Sarap; Tonia A Bivens; Tracy D McGuire; Ann Scheck McAlearney; Timothy R Huerta; Saurabh Rahurkar Journal: Implement Sci Commun Date: 2021-05-19
Authors: Krishna P Sharma; Scott D Grosse; Michael V Maciosek; Djenaba Joseph; Kakoli Roy; Lisa C Richardson; Harold Jaffe Journal: Prev Chronic Dis Date: 2020-10-08 Impact factor: 2.830
Authors: Frederick North; Elissa M Nelson; Rebecca J Buss; Rebecca J Majerus; Matthew C Thompson; Brian A Crum Journal: JMIR Med Inform Date: 2021-12-07